In her two years as a sales rep for Mountain View, CA-based Alza Corp., Suzy Porter has discovered that seeing results in patients' lives is her job's most rewarding aspect. A year ago, Porter established a support group for patients with interstitial cystitis, a disease that often evades diagnosis, can be left untreated for years and can severely disrupt day-to-day life. Its symptoms resemble "a constant urinary tract infection that is excruciatingly painful."
In her two years as a sales rep for Mountain View, CA-based Alza Corp., Suzy Porter has discovered that seeing results in patients' lives is her job's most rewarding aspect. A year ago, Porter established a support group for patients with interstitial cystitis, a disease that often evades diagnosis, can be left untreated for years and can severely disrupt day-to-day life. Its symptoms resemble "a constant urinary tract infection that is excruciatingly painful."
Porter recognized the need to provide patients with a source of education about interstitial cystitis and an outlet for their frustrations. Porter distributed flyers in doctors' offices, arranged meeting places and found a president to run the group, who also had interstitial cystitis. Porter continues to arrange for speakers â nutritionists, physical therapists, psychiatrists â to address different aspects of disease management.
According to Porter, the support group has provided relief not only to patients, but also to busy doctors. "If [patients'] problems tend to flare during the week, they'll call [their doctors] constantly. Now, patients have options, they can call people in their support group. I think the doctors really appreciate this additional source of information for patients."
Porter enjoys helping to improve the quality of patients' lives and building relationships with doctors and the patients in her support group. Porter expressed, "[Patients] know that I'm there to represent them as well as my company. I want to make sure that people are educated on interstitial cystitis and their treatment options."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.